Literature DB >> 14648435

[Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities].

F Lestin1, A Pertschy, D Rimek.   

Abstract

HISTORY AND CLINICAL
FINDINGS: A 48-year-old diabetic with multiple co-morbidities presented with generalized micro- and macroangiopathy including peripheral artery disease stage IV with necroses in several digits of both feet. He was admitted to the department of surgery for the insertion of femoropopliteal bypasses. INVESTIGATIONS: Infectious parameters were elevated (CRP 66.1 mg/l, sedimentation rate 90/96), accompanied by anemia (Hb 7.1 mmol/l), leukocytosis (14.8 Gpt/l) and thrombocytosis (514 Gpt/l). Body temperature was normal (36.8 degrees C). With insulin treatment the patient became nearly normoglycemic (HbA1c 6.8 %). TREATMENT AND FOLLOW UP: After receiving different broad-spectrum antibiotics over seven weeks the patient developed Clostridium difficile toxin-positive diarrhea that resolved after administration of oral metronidazole and Saccharomyces boulardii (Perenterol ((R))). Three days after bypass insertion, both legs had to be amputated due to infection and beginning sepsis. The condition of the patient improved. However, eight days after bypass-insertion the patient developed a toxic megacolon and sepsis. Blood cultures yielded the growth of Saccharomyces cerevisae. Despite of intensive care treatment the patient died five days later from to multi-organ failure.
CONCLUSION: S. boulardii (synonym: S. cerevisiae) is considered an non-pathogenic probiotic yeast, and live yeast cells are used for supportive therapy of diarrhea. The present case and a review of the literature demonstrate that fungemia and sepsis are rare complications of the administration of S. boulardii in immunocompromised patients. For this reason the therapeutic usage of probiotics should be carefully considered regarding its risk-benefit potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648435     DOI: 10.1055/s-2003-44948

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  10 in total

1.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 2.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 3.  Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Authors:  Iyad Issa; Rami Moucari
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 4.  Clostridium difficile infection.

Authors:  Latisha Heinlen; Jimmy D Ballard
Journal:  Am J Med Sci       Date:  2010-09       Impact factor: 2.378

5.  Probiotic use in the critically ill.

Authors:  Sunit C Singhi; A Baranwal
Journal:  Indian J Pediatr       Date:  2008-08-31       Impact factor: 1.967

Review 6.  Probiotics in critically ill children.

Authors:  Sunit C Singhi; Suresh Kumar
Journal:  F1000Res       Date:  2016-03-29

7.  Probiotic Survey in Cancer Patients Treated in the Outpatient Department in a Comprehensive Cancer Center.

Authors:  Sona Ciernikova; Michal Mego; Maria Semanova; Lenka Wachsmannova; Zuzana Adamcikova; Viola Stevurkova; Lubos Drgona; Vladimir Zajac
Journal:  Integr Cancer Ther       Date:  2016-05-05       Impact factor: 3.279

8.  Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients.

Authors:  Beata Sulik-Tyszka; Emilian Snarski; Magda Niedźwiedzka; Małgorzata Augustyniak; Thorvald Nilsen Myhre; Anna Kacprzyk; Ewa Swoboda-Kopeć; Marta Roszkowska; Jadwiga Dwilewicz-Trojaczek; Wiesław Wiktor Jędrzejczak; Marta Wróblewska
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609

9.  Effect of cultured white soft cheese on the histopathological changes in the kidneys and liver of albino rats.

Authors:  Khaled H Salman; Fatma Abo Zakaib Ali; Ruwaida Elhanbaly
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.379

10.  Probiotics for treating eczema.

Authors:  Areti Makrgeorgou; Jo Leonardi-Bee; Fiona J Bath-Hextall; Dedee F Murrell; Mimi Lk Tang; Amanda Roberts; Robert J Boyle
Journal:  Cochrane Database Syst Rev       Date:  2018-11-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.